Hook & thesis
Chewy is no longer just a revenue growth story; it's increasingly a cash-flow and margin story too. At today's price of $26.14 the market is pricing the company as a mid-single-digit margin e-commerce operator, yet management has concrete levers - Autoship penetration, a growing advertising business and healthcare/clinic rollouts - that should push EBITDA materially higher over the next 12 months. I view the current pullback as a disciplined buying opportunity for a position trade: enter at $26.00, protect with a $23.00 stop, and target $35.00 within a 180 trading-day horizon.
Why the market should care
Customers buy pet products routinely, which makes Chewy's top line stickier than many other e-commerce categories. News coverage notes Autoship contributes north of 80% of sales in recent quarters (coverage on 04/19/2026 and 04/24/2026 reports Autoship at roughly 83-84% of sales). That recurring revenue alone gives management predictable revenue and allows operating leverage to flow through into profit as logistics and marketing efficiencies improve.
Business overview and fundamental driver
Chewy operates an online-first retail ecosystem for pet supplies and services: core product commerce, a fast-growing advertising business (Chewy Ads), and a push into pet healthcare via pharmacy services and clinic rollouts following the Modern Animal acquisition. The core fundamental driver is a high-autoship repeat rate that reduces customer acquisition costs over time and increases lifetime value. That combination supports margin expansion as fixed fulfillment and technology costs spread over larger recurring order volumes.
Hard numbers that matter
- Current price: $26.14; previous close $25.65.
- Market cap: approximately $10.85 billion.
- Reported earnings per share: $0.54; reported P/E roughly 47.9x (most recent data point).
- Enterprise value: roughly $9.83 billion; EV/EBITDA ~25.6x.
- Free cash flow: $562.4 million (latest reported).
- Price-to-sales: ~0.85; price-to-free-cash-flow: ~19.
- Balance sheet/liquidity: current ratio ~0.88, quick ~0.51 (areas to watch).
Those metrics show a business producing meaningful cash flow but still priced like a growth company. Free cash flow of $562 million is a real anchor: if management sustains FCF growth while scaling gross margin, forward multiples compress quickly and the equity rerates higher. The buyback program (management tripled capacity to $750 million per coverage on 04/14/2026) is an immediate lever to amplify EPS and FCF per share if execution stabilizes.
Valuation framing
At a market cap near $10.8 billion and EV roughly $9.8 billion, Chewy is trading at EV/EBITDA of ~25.6x today. That multiple is elevated vs. mature retailers but reasonable for a company with a high recurring revenue mix and mid-teens long-term growth profile. Price-to-sales at ~0.85 is moderate for e-commerce names that historically trade above 1.0 when growth and margin prospects are strong. The current P/E near 48x reflects recent earnings volatility; the same multiple would meaningfully compress if EBITDA margins approach management's 10% target (public commentary and analyst coverage cite a 10% EBITDA target vs. a recent 5.7% reference point). In short, valuation is not screaming cheap, but it is actionable if the operating margin story plays out.
Technical and liquidity context
Recent technicals are neutral-to-constructive: RSI around 47.7, short-term EMAs slightly above price, and MACD showing a small bearish histogram reading. Average daily volume is healthy (several million shares), and short interest is economically modest with days-to-cover near ~2.5 on the most recent settlement - meaning squeezes are possible but not likely to be extreme. The 52-week range is $22.74 to $48.62, so the stock is closer to the low end of that band after the recent pullback.
Trade plan (actionable)
Thesis: Durable Autoship demand + advertising monetization + clinic/pharmacy expansion will drive margin expansion and free cash flow growth, supporting an equity rerating.
Entry: Buy at $26.00.
Stop loss: $23.00 - a defined cut under the recent low region that limits downside if customer or margin trends reverse.
Target: $35.00 over a long term (180 trading days) horizon.
Why these levels? Entry at $26 is near the current market price and lets you participate in near-term positive catalysts. The stop at $23 protects capital if Autoship durability weakens or if clinics prove more dilutive than expected. The $35 target assumes margin improvement and multiple expansion: move from the current EV/EBITDA level toward a slightly richer multiple as EBITDA approaches low-double-digit margins and FCF per share grows via buybacks.
Time horizon: long term (180 trading days). This trade requires patience: margin recovery, ad-monetization scale and clinic rollout benefits generally play out over quarters, not days. Expect volatility, but allow multiple quarters for operating leverage to materialize.
Catalysts (2-5)
- Quarterly results showing sequential margin expansion and accelerating free cash flow.
- Stronger-than-expected growth or monetization in Chewy Ads (ad revenue headline growth will be a multiple expansion driver).
- Clear performance data from Modern Animal clinic integrations showing attractive unit economics and cross-selling uplift to Autoship.
- Share buyback execution near the newly announced $750 million capacity, which will reduce shares outstanding and raise EPS/FCF per share.
Risks and counterarguments
Any trade has upside and downside; here's the balanced assessment.
- Macro consumer weakness: While pet spend is historically resilient, a deep consumer pullback could still dent discretionary pet spending and slow Autoship growth.
- Execution risk on clinics: Healthcare and clinic rollouts are capital intensive and operationally different from e-commerce. Poorly performing clinics could weigh on margins for several quarters.
- Valuation vulnerability: The current P/E near ~48x and EV/EBITDA ~25.6x leave limited room for disappointment; missing margin or growth targets could trigger sharp multiple compression.
- Liquidity/working capital stress: Current ratio around 0.88 and quick ratio near 0.51 indicate limited short-term liquidity cushion; aggressive inventory build or receivable timing could stress the balance sheet if not managed.
- Competition: Large retailers and marketplaces (incumbent supermarkets, Amazon) operate on low-cost bases and could pressure pricing or ad monetization fees.
Counterargument: The simple view is that Chewy still trades at growth company multiples and any slip in margin recovery or a slower-than-expected rollout of high-margin initiatives (Ads or clinics) will make the stock expensive relative to realized earnings. The market could rerate lower before the company proves out the margin thesis.
What would change my mind?
I would reduce conviction or close the trade if quarterly results show: (1) Autoship penetration materially falling below the 80%-plus range cited recently, (2) sequential declines in free cash flow instead of growth, (3) clinic unit economics that are consistently dilutive to consolidated margins, or (4) management suspending or reversing buybacks. Conversely, faster-than-expected ad revenue growth or a demonstrable move toward a 10% EBITDA margin would increase position size.
Conclusion
Chewy is a pragmatic long opportunity trading at $26.14 today. The company's recurring Autoship base, ad-monetization path and healthcare expansion give it multiple credible levers for sustainable margin improvement. Those levers are already visible in free cash flow generation ($562 million) and management's decision to expand buyback capacity to $750 million. The trade is not without risk - valuation leaves little room for execution missteps - but I prefer a structured long: entry $26.00, stop $23.00, target $35.00, horizon 180 trading days. Monitor Autoship metrics, ad revenue cadence and clinic economics closely; they will determine whether this thesis plays out or needs to be re-evaluated.